Four pillars of intelligence for the questions that matter most in drug development: who is competing, which candidates will succeed, where the opportunities lie, and what stealth companies are building before they announce.
Who else is working on similar drugs?
Map the competitive field for any drug target or modality. See which companies have programs at each clinical stage, where target overlap is densest, and how deal activity shapes who controls which assets.
Capabilities
Interactive company-by-target grid showing clinical phase for each program across the TPD field.
ExploreCurated pipeline, financials, and partnership data for tracked companies.
ExploreLive AACT queries for degraders, molecular glues, and kinase inhibitors: phase breakdowns, top sponsors, and sample trials.
ExploreThe AI chat can query the curated TPD matrix directly: filter by target, company, modality, phase, and disease area. Ask natural-language questions about competitive overlap.
ExploreParameterized SQL by target, sponsor, drug, condition, phase, and modality in AI chat: not just four fixed presets.
ExploreStructured deal flow data (acquirer, value, structure) for competitive context.
ExploreExample questions
Which drug candidates are likely to succeed?
Evaluate drug candidates by trial design quality, enrollment momentum, regulatory designations, published interim data, and safety signals. Cross-reference with literature to assess probability of success.
Capabilities
Full protocol: eligibility, endpoints, arms, sites, enrollment, and whether results are posted.
ExplorePubMed-powered search for trial results, systematic reviews, and interim analyses.
ExploreSide-by-side comparison of 2 to 4 trials: design, endpoints, enrollment, and status.
ExploreThe AI chat can retrieve deep curated target profiles (mechanism, pathway, diseases, degradation rationale) for STAT6, IRAK4, and IRF5 to contextualize trial data.
ExploreStructured parsing of CT.gov posted outcome measures and statistical results.
FDA breakthrough therapy, fast track, priority review, and orphan drug designations as success predictors.
Example questions
Where can new drugs do better?
Identify where existing drug candidates have known limitations: narrow therapeutic windows, poor CNS penetration, resistance mechanisms, or unaddressed patient populations. Map white-space targets and underserved indications.
Capabilities
Deep target narratives: mechanism, pathway, disease relevance, and known limitations of current approaches.
ExploreBioactivity data (IC50, Ki) for compounds against specific targets, revealing selectivity and potency gaps.
ExploreTargets with disease validation but no clinical-stage programs in the competitive matrix.
ExploreThe AI chat can retrieve curated target profiles with degradation rationale, disease context, and competitive gaps to identify where new drugs could improve upon existing candidates.
ExploreQuery the TPD matrix from AI chat to find white-space targets and underserved indications where no company has clinical programs.
ExploreClass-level FAERS analysis to identify adverse event profiles that new drugs could improve upon.
Freedom-to-operate analysis and identification of expiring composition-of-matter patents.
Example questions
What are new companies working on before they announce?
Stealth-mode biotechs leave breadcrumbs across public registries, patent filings, grant databases, scientific publications, and conference abstracts. Triangulating these signals reveals emerging competitors before press releases.
Capabilities
Monitor AACT for trial registrations from sponsors not in the tracked competitive set. Flag new entrants in watched therapeutic areas.
WHO ICTRP scan for novel programs registered in ChiCTR, EU CTR, or other international registries before US filing.
Track SBIR/STTR and R01 grants in target areas to identify academic-to-clinical translation signals.
Scan bioRxiv, medRxiv, and conference abstract databases for novel compound disclosures by unknown entities.
Monitor new patent applications (CPC classification) for composition-of-matter claims on novel degraders or targets.
Triangulate registry, patent, publication, and grant signals into a confidence score for emerging competitor identification.
Example questions
Emerging drug intelligence combines curated company data with live registry queries. Phase classifications reflect the highest reported clinical stage; always verify against primary sources. This is not investment advice.